The Medicines Optimisation Review Toolkit Evaluation in HIV Outpatients
NCT03340077 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 200
Last updated 2021-05-07
Summary
Multicentre, randomised (1:1), controlled, open (not blinded) comparison of MOR toolkit (intervention) with standard pharmaceutical care (control)
Conditions
Interventions
- OTHER
-
Medicines Optimisation Review toolkit
The Review tool consist of two items. 'My Clinic companion' and 'MOR consultation form'. 'My clinic companion' (see appendix 1) is a patient-orientated questionnaire that promotes self-review of medications and adherence and will facilitate the pharmacist consultation. The 'MOR consultation form' (see appendix 2), is designed to aid a structured patient consultation using available information from local databases, GP medication histories as well as that obtained directly from the patient. The form also identifies key care providers involved in the patient case, including prior consent to contact with information if required.
- OTHER
-
Standard of Care
Pharmacist review of ART medications
Sponsors & Collaborators
- collaborator INDUSTRY
-
Brighton and Sussex University Hospitals NHS Trust
lead OTHER
Principal Investigators
-
Jaime Vera, MD · University of Sussex
Study Design
- Allocation
- RANDOMIZED
- Purpose
- SUPPORTIVE_CARE
- Masking
- NONE
- Model
- PARALLEL
Eligibility
- Min Age
- 18 Years
- Sex
- ALL
- Healthy Volunteers
- No
Timeline & Regulatory
- Start
- 2018-02-06
- Primary Completion
- 2019-12-31
- Completion
- 2019-12-31
Countries
- United Kingdom
Study Locations
More Related Trials
-
Open Label Study of 908/RTV in Combination With Other PIs for the Treatment of Multi PI-Experienced HIV Subjects
NCT00144833 ·Status: TERMINATED ·Phase: PHASE3
-
Pharmacokinetics, Safety And Toleration Of Maraviroc Administered To Subjects With Various Degrees Of Renal Impaired And Normal Renal Function
NCT00717067 ·Status: COMPLETED ·Phase: PHASE4
-
A Study of 1592U89 Combined With Other Anti-HIV Drugs in Patients Who Have Taken Anti-HIV Drugs
NCT00002364 ·Status: COMPLETED ·Phase: PHASE2
-
Study to Evaluate a HIV Drug for the Treatment of HIV Infection
NCT01803074 ·Status: COMPLETED ·Phase: PHASE2
-
The Effects of Ageing on the 'Pharmacokinetic and Clinical Observations in People Over Fifty'
NCT01737047 ·Status: COMPLETED
-
Pharmacokinetics of Maraviroc and Boosted Atazanavir Dual Regimen in Stable HIV-infected Patients
NCT03708861 ·Status: WITHDRAWN ·Phase: PHASE3
-
Microboosting of Atazanavir 300 mg With 50 mg Versus 100mg Ritonavir Daily in HIV-infected Patients: a Pharmacokinetic Study
NCT02034838 ·Status: COMPLETED ·Phase: PHASE1
-
A Dose-Frequency Trial of Oral Retrovir in Patients With AIDS or Severe ARC
NCT00002046 ·Status: COMPLETED ·Phase: NA
-
A Phase IV, Open-label Single-arm Study Investigating the Pharmacokinetics and Pharmacodynamics of the Antiretroviral Combination of Rilpivirine and Ritonavirboosted Darunavir in Therapy-naive HIV-1 Infected Patients.
NCT01736761 ·Status: COMPLETED ·Phase: PHASE4
-
Study to Evaluate the Influence of Nevirapine to Atazanavir in Steady State Equilibrium in HIV Patients
NCT00355719 ·Status: COMPLETED ·Phase: PHASE4
-
A Trial of 2 Options for Second Line Combination Antiretroviral Therapy Following Virological Failure of a Standard Non-nucleoside Reverse Transcriptase Inhibitor (NNRTI)+2N(t)RTI First Line Regimen
NCT00931463 ·Status: COMPLETED ·Phase: PHASE4
-
Albuvirtide in Combination With 3BNC117 in Virologically Suppressed Subjects With HIV-1 Infection
NCT04819347 ·Status: UNKNOWN ·Phase: PHASE2
-
Phase IIIb Study to Evaluate the Effectiveness and Safety of Atazanavir/Ritonavir as Single Enhanced Protease Inhibitor Therapy in Human Immunodeficiency Virus (HIV)-Infected Subjects Evidencing Virologic Suppression
NCT00337467 ·Status: COMPLETED ·Phase: PHASE3
-
Study of Lopinavir/ Ritonavir and Lamivudine Versus Standard Therapy in Naïve HIV-1 Infected Subjects.
NCT01237444 ·Status: COMPLETED ·Phase: PHASE3
-
Drug Interaction Study
NCT00646776 ·Status: COMPLETED ·Phase: PHASE1
-
A Study in Asymptomatic HIV Infected Patients to Investigate Pharmacodynamics, Pharmacokinetics, Safety and Toleration of UK-453,061
NCT00348673 ·Status: COMPLETED ·Phase: PHASE2
-
Albuvirtide and 3BNC117 as Long-Acting Maintenance Therapy in Virologically Suppressed Subjects
NCT03719664 ·Status: UNKNOWN ·Phase: PHASE2
-
Safety and Efficacy of E/C/F/TDF Versus RTV-Boosted ATV Plus FTC/TDF in HIV-1 Infected, Antiretroviral Treatment-Naive Women
NCT01705574 ·Status: COMPLETED ·Phase: PHASE3
-
Long-Term Data Collection From Participants in Adult AIDS Clinical Trials
NCT00001137 ·Status: COMPLETED
-
Letermovir in ART-treated HIV-infected Persons
NCT05362916 ·Status: COMPLETED ·Phase: NA
-
A Phase IIIb Study Comparing Two Boosted Protease Inhibitor-based HAART Regimens in HIV-infected Patients Experiencing Their First Virologic Failure While Receiving an NNRTI-containing HAART Regimen
NCT00135395 ·Status: COMPLETED ·Phase: PHASE3
-
Efficacy, Safety, and ToLerability of Switching to A Two-Drug Regimen With DTG/3TC Compared to Maintaining A Three-Drug REgimen With BIC/FTC/TAF or DTG/3TC/ABC in ViroLogically SupprEssed PeopLe Living With HIV After 24 and 48 Weeks of Follow-Up
NCT07138144 ·Status: RECRUITING ·Phase: PHASE4
-
Saquinavir/Ritonavir in Single Therapy as Maintenance Treatment
NCT00379405 ·Status: COMPLETED ·Phase: PHASE4
-
Dose Ranging Trial of Tipranavir/Ritonavir in Treatment-Experienced HIV Infected Individuals
NCT00034866 ·Status: COMPLETED ·Phase: PHASE2
-
Study Comparing Lopinavir/Ritonavir (LPV/r) + Emtricitabine/Tenofovir Disoproxil Fumarate (FTC/TDF) With a Nucleoside Sparing Regimen Consisting of Lopinavir/Ritonavir + Raltegravir (RAL)
NCT00711009 ·Status: COMPLETED ·Phase: PHASE3